Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000155655 | SCV000205364 | likely benign | not specified | 2013-04-17 | criteria provided, single submitter | clinical testing | Gly158Ser in exon 4 of PRKAG2: This variant is not expected to have clinical sig nificance due to a lack of evolutionary conservation. Of note, multiple mammals (including mouse, rat, squirrel, and rabbit) have a serine (Ser) at this positio n despite high nearby amino acid conservation. In addition, computational analys es (AlignGVGD, PolyPhen2, SIFT) do not suggest a high likelihood of impact to th e protein and the variant is located outside the CBS domain region where all pat hogenic PRKAG2 variants have been identified to date (Oliveira 2003). |
Gene |
RCV001719977 | SCV000208936 | likely benign | not provided | 2021-02-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000457420 | SCV000561809 | likely benign | Lethal congenital glycogen storage disease of heart | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000155655 | SCV000918093 | likely benign | not specified | 2017-12-11 | criteria provided, single submitter | clinical testing | Variant summary: The PRKAG2 c.472G>A (p.Gly158Ser) variant involves the alteration of a conserved nucleotide. 2/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index). This variant was found in 141/277028 control chromosomes in gnomAD (1 homozygote) at a frequency of 0.000509, which is approximately 20 times the estimated maximal expected allele frequency of a pathogenic PRKAG2 variant (0.000025), suggesting this variant is likely a benign polymorphism. The variant of interest has not, to our knowledge, been reported in affected individuals via publications; nor evaluated for functional impact by in vivo/vitro studies. In addition, multiple clincial labs classified this variant as likely benign and one other lab classified it as VUS, all without evidence for independent evaluation. Taken together, this variant is classified as likely benign. |
Color Diagnostics, |
RCV001177593 | SCV001341830 | likely benign | Cardiomyopathy | 2018-12-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002336332 | SCV002635921 | likely benign | Cardiovascular phenotype | 2019-04-26 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |